Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05851677
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Sponsor: RenJi Hospital
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Official title: Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
45
Start Date
2023-06-01
Completion Date
2027-08
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
DRUG
Disitamab vedotin
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China